Pure Biologics Spólka Akcyjna
PUR.WA
Warsaw Stock Exchange2.10
PLN
- -
- -
Pure Biologics Spólka Akcyjna
PUR.WA
(Warsaw Stock Exchange)
Recent
price
2.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research, development, and production of innovative biological drugs and non-systemic therapies targeting immuno-oncology, autoimmunology, and rare neurological diseases; it specializes in the discovery and optimization of therapeutic antibodies and aptamers, including the PureApta modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic applications; the company also provides services for antibody and aptamer production, purification, analysis, characterization, and assay design, development, and validation, as well as gene-to-protein services encompassing sequence optimization, vector construction, biomass production using bacterial and mammalian expression platforms, protein refolding from inclusion bodies, and bioanalytical evaluations such as mass spectrometry, dynamic light scattering, circular dichroism, size-exclusion chromatography, surface plasmon resonance, and ELISA. Pure Biologics Spólka Akcyjna operates primarily from its headquarters in Wroclaw, Poland, where it was founded in 2010, and serves pharmaceutical companies, biotechnology firms, and academic research laboratories with a focus on novel, non-generic antibody-based biological medicines. In December 2024, the company entered a strategic partnership agreement with Promittens Corporation to sell global rights to molecules PBA-0405 (project PB004), an IgG1 therapeutic antibody targeting ROR1 for B-cell malignancies and solid tumors via antibody-dependent cellular cytotoxicity, and PBA-0111 (project PB003G), a dual-action antibody targeting GARP to eliminate regulatory T cells and stimulate NK and T lymphocytes against solid tumors; this deal provides upfront fees of $8 million to $9 million contingent on Phase 0 clinical trial results, potential milestone payments up to $299 million, and royalties, following successful completion of the Phase 0 study for PBA-0405 in cancer treatment and FDA approval for PBA-0111's Phase 0 trial in head and neck cancers and soft tissue sarcomas.